{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:16:21Z","timestamp":1789416981227,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["IM4635608802"],"award-info":[{"award-number":["IM4635608802"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004240","name":"Akademie V\u011bd \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["IAAX00500803"],"award-info":[{"award-number":["IAAX00500803"]}],"id":[{"id":"10.13039\/501100004240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.jconrel.2009.07.011","type":"journal-article","created":{"date-parts":[[2009,7,25]],"date-time":"2009-07-25T09:38:44Z","timestamp":1248514724000},"page":"18-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity"],"prefix":"10.1016","volume":"140","author":[{"given":"Tom\u00e1\u0161","family":"Etrych","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Strohalm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubom\u00edr","family":"Kov\u00e1\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kabe\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanka","family":"\u0158\u00edhov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Ulbrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2009.07.011_bib1","series-title":"The Practice of Medicinal Chemistry","first-page":"717","article-title":"Macromolecular carriers for drug targeting","author":"Schacht","year":"1996"},{"key":"10.1016\/j.jconrel.2009.07.011_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(99)00141-8","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation","volume":"64","author":"Ulbrich","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1958","article-title":"Polymer conjugates as anticancer nanomedicines","volume":"6","author":"Duncan","year":"2006","journal-title":"Natl. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2009.07.011_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/cmdc.200700159","article-title":"Prodrug strategies in anticancer chemotherapy","volume":"3","author":"Kratz","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2009.07.011_bib5","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0168-3659(99)00140-6","article-title":"Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anticancer activity of Ab or (Fab\u2032)2-targeted conjugates and combined theraphy with immunomodulators","volume":"64","author":"\u0158\u00edhov\u00e1","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/anie.200502113","article-title":"Polymer therapeutics: concepts and applications","volume":"45","author":"Haag","year":"2006","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2009.07.011_bib7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(01)00227-7","article-title":"Targeted drug conjugates: principles and progress","volume":"53","author":"Garnet","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2009.07.011_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-3659(01)00330-3","article-title":"Water soluble polymers in tumor targeted delivery","volume":"74","author":"Kope\u010dek","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/bc980126+","article-title":"A versatile method for the conjugation of proteins and peptides to poly[2-(dimethylamino)ethyl methacrylate]","volume":"10","author":"van Dijk-Wolthuis","year":"1999","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.jconrel.2009.07.011_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/masy.19961030118","article-title":"Polymeric conjugates of drugs and antibodies for site-specific drug delivery","volume":"103","author":"Ulbrich","year":"1996","journal-title":"Macromol. Symp."},{"key":"10.1016\/j.jconrel.2009.07.011_bib11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/3540587888_14","article-title":"Polymer conjugates with anticancer activity","volume":"122","author":"Putnam","year":"1995","journal-title":"Adv. Polym. Sci."},{"key":"10.1016\/j.jconrel.2009.07.011_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.addr.2003.10.040","article-title":"Polymeric anticancer drugs with pH-controlled activation","volume":"56","author":"Ulbrich","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2009.07.011_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v16.i3.10","article-title":"Drug\u2013polymer conjugates containing acid-cleavable bonds","volume":"16","author":"Kratz","year":"1999","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2009.07.011_bib14","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1016\/j.bmc.2006.02.007","article-title":"Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity","volume":"14","author":"Rodrigues","year":"2006","journal-title":"Bioorganic Med. Chem."},{"key":"10.1016\/j.jconrel.2009.07.011_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/0090-1229(88)90010-4","article-title":"Antibody directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting","volume":"46","author":"\u0158\u00edhov\u00e1","year":"1988","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.jconrel.2009.07.011_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0168-3659(95)00198-0","article-title":"Cytotoxic and cytostatic effects of anti-Thy 1.2 targeted doxorubicin and cyclosporin A","volume":"40","author":"\u0158\u00edhov\u00e1","year":"1996","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0168-3659(03)00340-7","article-title":"HPMA copolymer-bound doxorubicin conjugate targeted to tumor specific antigen of BCL1 mouse B cell leukemia","volume":"92","author":"Kov\u00e1\u0159","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib18","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1023\/A:1026170830782","article-title":"Star-like versus classical macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs","volume":"20","author":"Jel\u00ednkov\u00e1","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2009.07.011_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-006-0168-0","article-title":"Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces systemic and long-lasting anti-tumor immunity in mice","volume":"56","author":"\u0160\u00edrov\u00e1","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2009.07.011_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(03)00235-9","article-title":"Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data","volume":"91","author":"\u0158\u00edhov\u00e1","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6604483","article-title":"Tumour-targeted nanomedicines: principles and practice","volume":"99","author":"Lammers","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2009.07.011_bib22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.jconrel.2009.07.011_bib23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/0959-8049(94)00514-6","article-title":"Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier","volume":"3","author":"Seymour","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2009.07.011_bib24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0168-3659(02)00348-6","article-title":"HPMA copolymers with pH-controlled release of doxorubicin. In vitro cytotoxicity and in vivo antitumor activity","volume":"87","author":"Ulbrich","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/10611860400011869","article-title":"Antibody-targeted polymer\u2013doxorubicin conjugates with pH-controlled activation","volume":"12","author":"Ulbrich","year":"2004","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2009.07.011_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jconrel.2007.06.007","article-title":"Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy","volume":"122","author":"Etrych","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/bc00024a015","article-title":"(6-maleimidocaproyl) hydrazone of doxorubicin\u2014a new derivative for the preparation of immunoconjugates of doxorubicin","volume":"4","author":"Willner","year":"1993","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.jconrel.2009.07.011_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1021\/bc980100i","article-title":"Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: a novel method for increasing the potency of doxorubicin immunoconjugates","volume":"10","author":"King","year":"1999","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.jconrel.2009.07.011_bib29","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nchembio786","article-title":"Site-specific PEGylation of native disulfide bonds in therapeutic proteins","volume":"2","author":"Shaunak","year":"2006","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.jconrel.2009.07.011_bib30","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1002\/app.28466","article-title":"N-(2-hydroxypropyl)methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation","volume":"109","author":"Etrych","year":"2008","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.jconrel.2009.07.011_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/bm050524x","article-title":"Coating of DNA\/poly(l-lysine) complexes by covalent attachment of poly[N-(2-hydroxypropyl)methacrylamide]","volume":"7","author":"\u0160ubr","year":"2006","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2009.07.011_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/1616-5195(20020101)2:1<43::AID-MABI43>3.0.CO;2-8","article-title":"Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity","volume":"2","author":"Etrych","year":"2002","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2009.07.011_bib33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0003-9861(58)90014-6","article-title":"Tissue sulfhydryl groups","volume":"74","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jconrel.2009.07.011_bib34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0168-3659(92)90181-P","article-title":"Polymers containing enzymatically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly-[2-(hydroxypropyl)methacrylamide] drug carriers in vitro and antitumour activity measured in vivo","volume":"18","author":"\u0160ubr","year":"1992","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0168-3659(01)00281-4","article-title":"New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties","volume":"73","author":"Etrych","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.07.011_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/10430340050015798","article-title":"Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20","volume":"11","author":"Introna","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2009.07.011_bib37","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing lymph nodes","volume":"91","author":"Golay","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jconrel.2009.07.011_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(64)92345-1","article-title":"Cytology of Burkitt's tumour (African lymphoma)","volume":"1","author":"Pulvertaft","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2009.07.011_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0168-3659(01)00320-0","article-title":"Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes","volume":"74","author":"\u0158\u00edhov\u00e1","year":"2001","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365909005045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365909005045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:23:17Z","timestamp":1759159397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365909005045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0168365909005045"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2009.07.011","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2009.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}